Clinical Trial

DOAC in Patients with Child a or B Liver Cirrhosis

Study acronym: CIRROAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to investigate pharmacokinetics and pharmacodynamics of direct oral anticoagulant drugs (DOAC), specifically apixaban and edoxaban, in patients with Child A or B liver cirrhosis (LC). The primary objective of this study is to verify the ability of apixaban and edoxaban to decrease in vivo thrombin generation in LC patients. Participants will be randomly assigned to either apixaban (Eliquis®) or edoxaban (Lixiana®) at a therapeutic dosage for 7 consecutive days. The results of this investigation will contribute to designing a prospective multicentre interventional study to investigate the efficacy of DOAC to improve clinical outcomes in patients with LC
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-19; most recent amendment 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2024-01-18
Trial Details
NCT Number NCT05869591
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions Liver Cirrhosis
Enrollment 40 participants
Start Date 2024-01-18
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-02-13